Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K Abou-Alfa, Anthony B El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro
Topics & Concepts
NivolumabMedicineSorafenibHepatocellular carcinomaInternal medicineOncologyCancer researchPhase (matter)CarcinomaPhases of clinical researchRenal cell carcinomaClinical trialImmunotherapyHepatocellular cancerHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersLiver physiology and pathology